Tuberculosis in travellers

Travel Medicine and Infectious Disease

Volumn 1, Issue 4, 2003, Pages 205-212

  Johnston, Victoria J ^a   Grant, Alison D ^a,b  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Preventive medicine; Travel; Tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BCG VACCINATION; BRAZIL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COUNSELING; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; ENVIRONMENTAL EXPOSURE; GAS MASK; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDUSTRIALIZATION; INFECTION PREVENTION; INFECTION RISK; LEISURE; LIVER TOXICITY; MEDICAL RESEARCH; MYCOBACTERIUM BOVIS; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE HEALTH SERVICE; PREVENTIVE MEDICINE; PRIMARY TUBERCULOSIS; PRIORITY JOURNAL; REVACCINATION; RISK ASSESSMENT; RISK REDUCTION; TRAVEL; TREATMENT INDICATION; TREATMENT PLANNING; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM; UNITED STATES; VENTILATOR; WORLD HEALTH ORGANIZATION;

EID: 15744390756     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2003.11.002     Document Type: Article

References (52)

1. World Health Organization, Stop TB Annual Report 2001. Geneva: World Health Organisation; 2002. WHO/CDS/STB/2002.17.
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
3. Menzies D. Controlling tuberculosis among foreign born within industrialized countries: expensive band-aids. Am J Respir Crit Care Med 2001;164:914-915.
4. Zuckerman JN. Recent developments: travel medicine. BMJ 2002;325:260-264.
5. Centers for Disease Control and Prevention, Essential components of a tuberculosis prevention and control program; and screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb Mortal Wkly Rep 1995;44:1-34.
6. Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med 1998;158:1871-1875.
7. Saiman L, San Gabriel P, Schulte J, Vargas MP, Kenyon T, Onorato I. Risk factors for latent tuberculosis infection among children in New York City. Pediatrics 2001;107:999-1003.
8. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Association of tuberculin sensitivity in Dutch adults with history of travel to areas of with a high incidence of tuberculosis. Clin Infect Dis 2001;33:300-304.
9. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000;356:461-465.
10. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-226.
11. Houston S. Tuberculosis risk and prevention in travelers - what about BCG? J Travel Med 1997;4:76-82.
12. Barrett-Connor E. The epidemiology of tuberculosis in physicians. JAMA 1979;241:33-38.
13. Brewer TF, Colditz GA. Bacille Calmette-Guerin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995;20:136-142.
14. Chan JC, Tabak JI. Risk of tuberculous infection among house staff in an urban teaching hospital. South Med J 1985;78:1061-1064.
15. Malasky C, Jordan T, Potulski F, Reichman LB. Occupational tuberculous infections among pulmonary physicians in training. Am Rev Respir Dis 1990;142:505-507.
16. Meredith S, Watson JM, Citron KM, Cockcroft A, Darbyshire JH. Are healthcare workers in England and Wales at increased risk of tuberculosis? BMJ 1996;313:522-525.
17. World Health Organization, Tuberculosis and air travel: guidelines for prevention and control. Geneva: World Health Organization; 1998. WHO/TB/98.256.
18. Rieder HL. Risk of travel-associated tuberculosis. Clin Infect Dis 2001;33:1393-1396.
19. Ormerod P. Tuberculosis and travel. Hosp Med 2000;61:171-173.
20. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-138.
21. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000;152:247-263.
22. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997;119:183-201.
23. D'Arcy Hart P, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council. BMJ 1977;2:293-295.
24. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550.
25. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345-1349.
26. Antonucci G, Girardi E, Raviglione MC, Ippolito G, for the Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 1995;274:143-148.
27. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997;11:875-882.
28. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457.
29. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000;14:1985-1991.
30. McCarthy OR. Asian immigrant tuberculosis - the effect of visiting Asia. Br J Dis Chest 1984;78:248-253.
31. Ormerod LP, Green RM, Gray S. Are there still effects on Indian Subcontinent ethnic tuberculosis of return visits ?: a longitudinal study 1978-97. J Infect 2001;43:132-134.
32. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000;55:887-901.
33. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-1158.
34. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-1345.
35. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of Bacillus Calmette-Guérin vaccine. Clin Infect Dis 1995;20:982-991.
36. ten Dam HG, Pio A. Pathogenesis of tuberculosis and effectiveness of BCG vaccination. Tubercle 1982;63:225-233.
37. Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. Issues relating to the use of BCG in immunization programmes. Geneva: World Health Organization; 1999. WHO/V&B/99.23.
38. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200-207.
39. Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991;143:490-495.
40. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
41. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850.
42. Centers for Disease Control and Prevention, Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep 2000;49(RR-6):1-51.
43. CDC, Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. Morb Mortal Wkly Rep 2003;52:735-739.
44. Nolan C, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. JAMA 1999;281:1014-1018.
45. Cobelens FG, Draayer-Jansen EW, Schepp-Beelen JC, van Gerven PJ, van Kessel RJ, van Deutekom H. Limited tuberculin screening participation amongst travellers to countries with high tuberculosis incidence; reason to consider BCG vaccination for some travellers. Ned Tijdschr Geneeskd 2003;147:561-565.
46. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999;3:962-975.
47. Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163:824-828.
48. Ferebee S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
49. Rodger A, Jaffar S, Paynter S, Hayward A, Carless J, Maguire H. Delay in the diagnosis of pulmonary tuberculosis, London, 1998-2000: analysis of surveillance data. BMJ 2003;326:909-910.
50. World Health Organization, International travel and health. Geneva: World Health Organisation; 2003.
51. Department of Health. Health information for overseas travel. London: The Stationery Office, 2001.
52. Centers for Disease Control and Prevention, Health information for international travel 2003-2003. Atlanta: US Department of Health and Human Services, Public Health Service; 2003.